Functional Diagnostics in Oklahoma

Sway Medical is an FDA-cleared Class II medical device software platform that provides objective assessment testing for concussion, balance, cognition, and functional movement via mobile devices. The platform serves athletic trainers, sports medicine professionals, physical therapists, and healthcare systems across the United States and internationally, with over 5,000 organizations and 60+ peer-reviewed research studies validating its technology. Sway's offerings include baseline testing (20 minutes), sideline evaluation (5 minutes), and return-to-learn/return-to-play protocols, replacing legacy platforms such as ImPACT, SCAT5, C3Logix, and King-Devick. The platform comprises 40+ tests across four domains: balance (using patented mobile sensor technology), cognition (visual processing speed, neuromotor response, inhibition control, memory, executive function), functional movement (accelerometer-based three-dimensional assessment), and surveys (30+ questionnaires including symptom checklists, Glasgow Coma Scale, cervical spine assessment, red flags, Maddocks, observable signs). Features include remote testing capability, HIPAA and FERPA compliance, EMR integration, customizable protocols, secure comprehensive reporting, and multi-language support. The company was acquired by Healthy Roster, a leading electronic medical record system for athletic trainers. Regulatory: FDA 510(k) cleared; built with security and quality management frameworks appropriate for Class II medical devices.

Acarix AS is a cardiac diagnostics company specializing in point-of-care acoustic-based diagnostic solutions for early coronary artery disease (CAD) assessment. The company's flagship product, CADScor® System, uses highly sensitive acoustic technology and advanced computational processing to analyze coronary blood flow and calculate patient-specific CAD risk scores. The system provides non-invasive, radiation-free risk stratification for patients presenting with chest pain or shortness of breath, with demonstrated negative predictive value of at least 96%. CADScor® System has been deployed in over 60,000 patient assessments since 2017 and is supported by 15+ years of research and development covered by 45 patents. The technology has received FDA De Novo clearance as a diagnostic aid for symptomatic patients with suspected CAD and is CE-marked in accordance with EU MDR 2017/745. Clinical evidence from multiple published studies involving over 6,000 patients demonstrates the system's diagnostic performance and utility compared to standard stress testing. The platform enables immediate risk stratification at point of care, potentially reducing unnecessary advanced diagnostic procedures in up to 40% of patients. Acarix targets healthcare professionals and facilities seeking accessible, cost-effective cardiac risk assessment tools that can be deployed regardless of geographical location or socioeconomic constraints.